Hasbro Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy LLY?
Source: Benzinga
Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, providing ratings and price targets for their stocks.
Solstice Advanced Materials: RBC Capital's Arun Viswanathan rated Solstice Advanced Materials (SOLS) as Sector Perform with a price target of $50, while shares closed at $47.49.
Ascentage Pharma Group: BTIG's Justin Zelin rated Ascentage Pharma (AAPG) as Buy with a price target of $50, with shares closing at $31.73.
Super League Enterprise and Hasbro: Aegis Capital rated Super League Enterprise (SLE) as Buy with a price target of $5, and Seaport Global rated Hasbro (HAS) as Buy with a price target of $100, with respective closing prices of $1.18 and $76.70.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1023.220
Low
950.00
Averages
1192
High
1500
Current: 1023.220
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
S&P 500 Bull Market Continues, Investor Confidence High
- Bull Market Performance: The S&P 500 finished 2025 with a remarkable 78% three-year increase, reflecting investor optimism particularly in high-growth sectors like artificial intelligence and weight loss drugs.
- Interest Rate Impact: The Federal Reserve's interest rate cuts have eased consumer financial pressure and facilitated borrowing for companies, which has driven stock prices and valuations higher, with the S&P 500's price-to-earnings ratio reaching historical highs.
- Valuation Fluctuations: Although the S&P 500 has shown little change recently, the Shiller CAPE ratio has declined for the first time, indicating that stock valuations may be coming down, which could signal potential market corrections ahead.
- Long-Term Investment Confidence: Despite potential short-term market fluctuations, historical data shows that the S&P 500 always recovers over the long term, encouraging investors to remain focused on economic reports and Fed signals to seize future investment opportunities.
See More
S&P 500 Index Enters Third Year of Bull Market
- Bull Market Performance: The S&P 500 finished 2023 with a double-digit gain, bringing its three-year increase to 78%, reflecting investor optimism particularly in high-growth sectors like artificial intelligence and weight loss drugs.
- Interest Rate Policy Impact: The Federal Reserve's interest rate cuts have eased consumer financial pressure and made borrowing easier for companies, further fueling stock market gains as investor expectations for economic improvement rise.
- Valuation Changes: The Shiller CAPE ratio for the S&P 500 recently declined for the first time in nearly a year, albeit slightly, marking the first sign of falling valuations; historical patterns suggest that such declines often precede stock market drops, prompting investor caution.
- Long-Term Investment Confidence: Despite potential short-term market fluctuations, the S&P 500 has historically shown resilience over the long term, indicating that investors holding quality stocks may experience limited impact from short-term downturns, with significant returns likely in the future.
See More
S&P 500 Index Surges Nearly 80% Over Three Years
- Bull Market Continuation: The S&P 500 index has entered a bull market since October 2023, achieving a double-digit gain by year-end, resulting in a 78% increase over three years, reflecting strong investor confidence in high-growth sectors, particularly in AI and weight loss drugs.
- Surging Valuations: As the S&P 500 has risen, stock valuations have reached historical highs, with the Shiller CAPE ratio exceeding 40 earlier this year, indicating optimistic expectations for future growth, yet raising concerns about sustainability.
- Interest Rate Policy Impact: The Federal Reserve's interest rate cuts have alleviated consumer burdens and facilitated corporate borrowing, further propelling the stock market; however, investor concerns regarding future rate changes may affect market sentiment, leading to volatility.
- Uncertain Market Outlook: Despite the recent slight decline in the Shiller CAPE ratio, historical data suggests that valuation drops often coincide with stock market declines, prompting investors to monitor economic reports and Fed communications to gauge future market direction.
See More
Novo Nordisk Faces Challenges and Opportunities Amid Setbacks
- Declining Performance: Novo Nordisk's disappointing guidance for fiscal year 2026 has led to a nearly 15% drop in stock price, reflecting pressures from intensified competition and government drug price negotiations that could impact long-term growth potential.
- New Product Launch: The launch of the oral version of Wegovy has seen rapid prescription growth, indicating its potential to generate new revenue streams despite market competition, which could help mitigate some of the company's challenges.
- Market Expansion: Eli Lilly's executive noted that Oral Wegovy is attracting mostly new patients, suggesting that it is not merely cannibalizing existing sales but effectively expanding the market, thereby enhancing Novo Nordisk's competitive position.
- Future Outlook: Despite the short-term sales decline challenges, Novo Nordisk is awaiting approval for new drugs like CagriSema and has several candidates in clinical trials; if progress is made, it could lead to a stock rebound, making it attractive for long-term investors.
See More
Novo Nordisk Faces Challenges and Opportunities Ahead
- Disappointing Earnings: Novo Nordisk reported disappointing fourth-quarter results and expects a sales decline in 2026, leading to a nearly 15% drop in stock price, highlighting pressures from increased competition and government drug price negotiations.
- Product Launch: The launch of the oral version of Wegovy has seen rapid prescription growth, indicating potential market expansion despite competitive pressures, which may attract new patients to Novo Nordisk's offerings.
- Market Expansion Potential: Eli Lilly's executive noted that the sales of Oral Wegovy are primarily from new patients, suggesting market expansion, which is a positive sign for Novo Nordisk, even as overall sales face challenges.
- Future Drug Development: Novo Nordisk is awaiting approval for CagriSema and is conducting clinical trials for other weight loss drugs; if successful, these developments could lead to a stock rebound, making it an attractive option for long-term investors.
See More
Novo Nordisk's Oral Wegovy Expands Weight Loss Market
- Market Expansion Potential: Novo Nordisk's oral Wegovy is experiencing rapid growth in prescription volume, indicating that it is not cannibalizing sales of the original formulation but rather expanding the weight loss market, showcasing strong demand and potential revenue growth opportunities.
- Increased Competitive Pressure: Despite the positive performance of oral Wegovy, Novo Nordisk expects a decline in sales for 2026, primarily due to intensified competition and government-led drug price negotiations, which could negatively impact the company's long-term financial health.
- New Drug Development Progress: Novo Nordisk is awaiting approval for CagriSema, a next-generation weight loss and diabetes therapy, and is also conducting several phase 2 and phase 3 clinical trials; if successful, these could provide new growth drivers for the company.
- Stock Price Volatility Risk: Novo Nordisk's shares have just hit a fresh 52-week low, and while there are high hopes for its new products, investors should exercise caution as analysts suggest the company is not among the current best stocks to invest in, potentially facing further stock price volatility.
See More
S&P 500 Bull Market Continues, Investor Confidence High
- Bull Market Performance: The S&P 500 finished 2025 with a remarkable 78% three-year increase, reflecting investor optimism particularly in high-growth sectors like artificial intelligence and weight loss drugs.
- Interest Rate Impact: The Federal Reserve's interest rate cuts have eased consumer financial pressure and facilitated borrowing for companies, which has driven stock prices and valuations higher, with the S&P 500's price-to-earnings ratio reaching historical highs.
- Valuation Fluctuations: Although the S&P 500 has shown little change recently, the Shiller CAPE ratio has declined for the first time, indicating that stock valuations may be coming down, which could signal potential market corrections ahead.
- Long-Term Investment Confidence: Despite potential short-term market fluctuations, historical data shows that the S&P 500 always recovers over the long term, encouraging investors to remain focused on economic reports and Fed signals to seize future investment opportunities.
See More
S&P 500 Index Enters Third Year of Bull Market
- Bull Market Performance: The S&P 500 finished 2023 with a double-digit gain, bringing its three-year increase to 78%, reflecting investor optimism particularly in high-growth sectors like artificial intelligence and weight loss drugs.
- Interest Rate Policy Impact: The Federal Reserve's interest rate cuts have eased consumer financial pressure and made borrowing easier for companies, further fueling stock market gains as investor expectations for economic improvement rise.
- Valuation Changes: The Shiller CAPE ratio for the S&P 500 recently declined for the first time in nearly a year, albeit slightly, marking the first sign of falling valuations; historical patterns suggest that such declines often precede stock market drops, prompting investor caution.
- Long-Term Investment Confidence: Despite potential short-term market fluctuations, the S&P 500 has historically shown resilience over the long term, indicating that investors holding quality stocks may experience limited impact from short-term downturns, with significant returns likely in the future.
See More
S&P 500 Index Surges Nearly 80% Over Three Years
- Bull Market Continuation: The S&P 500 index has entered a bull market since October 2023, achieving a double-digit gain by year-end, resulting in a 78% increase over three years, reflecting strong investor confidence in high-growth sectors, particularly in AI and weight loss drugs.
- Surging Valuations: As the S&P 500 has risen, stock valuations have reached historical highs, with the Shiller CAPE ratio exceeding 40 earlier this year, indicating optimistic expectations for future growth, yet raising concerns about sustainability.
- Interest Rate Policy Impact: The Federal Reserve's interest rate cuts have alleviated consumer burdens and facilitated corporate borrowing, further propelling the stock market; however, investor concerns regarding future rate changes may affect market sentiment, leading to volatility.
- Uncertain Market Outlook: Despite the recent slight decline in the Shiller CAPE ratio, historical data suggests that valuation drops often coincide with stock market declines, prompting investors to monitor economic reports and Fed communications to gauge future market direction.
See More
Novo Nordisk Faces Challenges and Opportunities Amid Setbacks
- Declining Performance: Novo Nordisk's disappointing guidance for fiscal year 2026 has led to a nearly 15% drop in stock price, reflecting pressures from intensified competition and government drug price negotiations that could impact long-term growth potential.
- New Product Launch: The launch of the oral version of Wegovy has seen rapid prescription growth, indicating its potential to generate new revenue streams despite market competition, which could help mitigate some of the company's challenges.
- Market Expansion: Eli Lilly's executive noted that Oral Wegovy is attracting mostly new patients, suggesting that it is not merely cannibalizing existing sales but effectively expanding the market, thereby enhancing Novo Nordisk's competitive position.
- Future Outlook: Despite the short-term sales decline challenges, Novo Nordisk is awaiting approval for new drugs like CagriSema and has several candidates in clinical trials; if progress is made, it could lead to a stock rebound, making it attractive for long-term investors.
See More
Novo Nordisk Faces Challenges and Opportunities Ahead
- Disappointing Earnings: Novo Nordisk reported disappointing fourth-quarter results and expects a sales decline in 2026, leading to a nearly 15% drop in stock price, highlighting pressures from increased competition and government drug price negotiations.
- Product Launch: The launch of the oral version of Wegovy has seen rapid prescription growth, indicating potential market expansion despite competitive pressures, which may attract new patients to Novo Nordisk's offerings.
- Market Expansion Potential: Eli Lilly's executive noted that the sales of Oral Wegovy are primarily from new patients, suggesting market expansion, which is a positive sign for Novo Nordisk, even as overall sales face challenges.
- Future Drug Development: Novo Nordisk is awaiting approval for CagriSema and is conducting clinical trials for other weight loss drugs; if successful, these developments could lead to a stock rebound, making it an attractive option for long-term investors.
See More
Novo Nordisk's Oral Wegovy Expands Weight Loss Market
- Market Expansion Potential: Novo Nordisk's oral Wegovy is experiencing rapid growth in prescription volume, indicating that it is not cannibalizing sales of the original formulation but rather expanding the weight loss market, showcasing strong demand and potential revenue growth opportunities.
- Increased Competitive Pressure: Despite the positive performance of oral Wegovy, Novo Nordisk expects a decline in sales for 2026, primarily due to intensified competition and government-led drug price negotiations, which could negatively impact the company's long-term financial health.
- New Drug Development Progress: Novo Nordisk is awaiting approval for CagriSema, a next-generation weight loss and diabetes therapy, and is also conducting several phase 2 and phase 3 clinical trials; if successful, these could provide new growth drivers for the company.
- Stock Price Volatility Risk: Novo Nordisk's shares have just hit a fresh 52-week low, and while there are high hopes for its new products, investors should exercise caution as analysts suggest the company is not among the current best stocks to invest in, potentially facing further stock price volatility.
See More
